Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
复制标题
评估 MYCN 表达作为神经母细胞瘤细胞标记物以通过 RT-PCR 检测微小残留病的初步研究。
DOI：
10.1097/01.mph.0000212976.13749.8a
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Danks,MaryK
中科院分区：
文献类型：
--
作者：
Wagner,LarsM;Burger,RebeccaA;Guichard,SylvieM;Raimondi,SusanaC;Santana,VictorM;Furman,WayneL;Barnette,Phillip;Danks,MaryK
This pilot study was performed to determine whether MYCN expression warrants further investigation as a tumor marker to detect low levels of residual neuroblastoma (NB). Seven NB cell lines and 30 bone marrow (BM) samples from patients with high-risk NB were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) for MYCN expression, and for the established NB marker tyrosine hydroxylase. MYCN was expressed in all 7 NB cell lines, but not in normal peripheral blood, CD34+ cells, or BM. In dilution studies using cell lines with or without DNA amplification of MYCN, 1 NB cell in 10 6 to 10 7 nucleated blood cells was detectable by RT-PCR. MYCN was identified in all 21 BM samples in which tumor cells were identified by histologic examination, including 4 samples in which tyrosine hydroxylase was not detected. Additionally, expression of both markers was detected in 5 samples that were negative by histology but presumably contained low levels of tumor cells, consistent with the greater sensitivity of RT-PCR compared with morphologic methods. Detection of MYCN RNA was independent of MYCN DNA amplification status. The selective expression of MYCN in tumor cells, and the sensitivity of detection of MYCN by RT-PCR noted in this and other studies, supports further evaluation of MYCN as a NB marker for molecular detection of minimal residual disease.
